CoChat

Trial watch: Immune checkpoint blockers for cancer therapy

Open access

The DOI matches its Crossref record; 317 of the 317 references it cites were found in a registry or an index.

Abstract

Immune checkpoint blockers (ICBs) are literally revolutionizing the clinical management of an ever more diversified panel of oncological indications. Although considerable attention persists around the inhibition of cytotoxic T lymphocyte-associated protein 4 (CTLA4) and programmed cell death 1 (PDCD1, best known as PD-1) signaling, several other co-inhibitory T-cell receptors are being evaluated as potential targets for the development of novel ICBs. Moreover, substantial efforts are being devoted to the identification of biomarkers that reliably predict the likelihood of each patient to obtain clinical benefits from ICBs in the absence of severe toxicity. Tailoring the delivery of specific ICBs or combinations thereof to selected patient populations in the context of precision medicine programs constitutes indeed a major objective of the future of ICB-based immunotherapy. Here, we discuss recent preclinical and clinical advances on the development of ICBs for oncological indications.

Overview

Integrity signals

Registry

Crossref · 10.1080/2162402x.2017.1373237

Cites

317 of 317 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 317 references

Research works printed but not linked: 3

  1. 2017, Cancer Discov., 7, 656
  2. Bezu L, 2015, Front Immunol., 6, 187
  3. Hammers HJ, 2017, J Clin Oncol., JCO2016721985

Cited by

See all 73

Metadata

Authors
Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., Zitvogel, L., Kroemer, G., & Galluzzi, L.
Affiliations
  • Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA
  • Weill Cornell Medicine (US)
  • Inserm (FR)
  • Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
  • Charles University (CZ)
  • Sotio a.c., Prague, Czech Republic
  • Université Paris-Sud (FR)
  • Karolinska University Hospital (SE)
Corresponding author
Galluzzi, Lorenzo
Venue
OncoImmunology
Published
2017-08-31
Volume
6
Issue
11
Pages
e1373237
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2750667003
Cited by
73
References
316
Citations by year
2026: 2 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 7 · 2021: 7 · 2020: 7 · 2019: 18 · 2018: 22 · 2017: 1
FWCI
1.38
Type
journal article
Language
en
Open access
Locations
  • OncoImmunology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
immune checkpoint inhibitors, CTLA-4, PD-1, biomarkers, predictive biomarkers, immunotherapy, precision medicine, cancer immunotherapy, clinical trials

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trial watch: Immune checkpoint blockers for cancer therapy. https://app.cochat.ai/papers/10.1080/2162402x.2017.1373237
The paper
Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2017). Trial watch: Immune checkpoint blockers for cancer therapy. OncoImmunology. https://doi.org/10.1080/2162402x.2017.1373237

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.